Keros Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $370.03 Mil.
During the past 12 months, Keros Therapeutics's average Total Assets Growth Rate was 40.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 121.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 72.10% per year.
During the past 6 years, Keros Therapeutics's highest 3-Year average Total Assets Growth Rate was 121.70%. The lowest was 82.40%. And the median was 91.70%.
Total Assets is connected with ROA %. Keros Therapeutics's annualizedROA % for the quarter that ended in Dec. 2023 was -46.24%. Total Assets is also linked to Revenue through Asset Turnover. Keros Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Keros Therapeutics Total Assets Historical Data
The historical data trend for Keros Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Keros Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (NAS:KROS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Keros Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Keros Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Keros Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Keros Therapeutics (Keros Therapeutics) Business Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KROS has been successfully added to your 